Alkermes
selective agonist showed dose dependent increased wakefulness and reduced cataplexy in preclinical models | Alkermes
Company
Deck date
January 2023
Slide
16 of 28
Similar slides by Alkermes
Investor Presentation
March 2023
Investor Day
March 2021
Related slides by other companies
IPO
July 2021
IPO
May 2021
Investor Presentation
December 2023
Results
May 2023
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io